Agreement with a leading cancer treatment group to advance the clinical development of Bria-OTS+ (breast cancer) and Bria-PROS+ (prostate cancer),…
Company maintains solid cash position of $158.9 millionSOUTH SAN FRANCISCO, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc.…
Five abstracts accepted for poster presentation highlight Company’s proprietary Conditionally Active Biologic (CAB) technologyDifferentiated preclinical activity for CAB anti-Nectin4-antibody drug…
Bionano will host a pre-conference scientific session that will include a live product demonstration of the Stratys™ system for high…
●Q4 and FY Revenue of $10.3 million and $40.2 million; a $8.4 million and 26% increase year-over-year ●Q4 and FY Income…
Moffitt’s preclinical findings strongly suggest PV-10 induces immunogenic cell death-associated immunogenicity in HPV-positive and HPV-negative HNSCC in vitro and in…
Alti Rahman and Susan Sabo-Wagner were selected as panelists at the Association of Cancer Care Centers event in Washington, D.C.…
MB-101 was well-tolerated and 50% of patients achieved stable disease or better with two partial responses and two complete responses…
NEW YORK, March 07, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery,…
• Dose escalation in FHD-286 combination study in AML continues to progress; clinical data anticipated in the second half of…